BreathScan OxiChek

McKesson Corporation has announced plans to form a new healthcare information technology company by partnering with software and analytics provider Change Healthcare Holdings.

McKesson and Change Healthcare will own a 70% and 30% stake respectively in the new company, which is aimed at addressing the healthcare industry’s emerging and most pressing challenges.

Upon completion of the transaction in the first half of next year, the partners will receive cash proceeds of $1.25bn and $1.75bn, respectively.

In a Series C preferred stock financing led by Vertex Healthcare, hearing solutions provider Earlens Corporation has raised $51m, which was split between $34m in new capital and $17m conversion of an outstanding bridge financing.

Earlens intends to complete the financing in Q3 this year by raising an additional $14m, which will be utilised to launch its Light Driven Hearing Aid.

Akers Biosciences has provided first distribution rights of BreathScan OxiChek, the company’s first disposable breath test to determine oxidative stress levels, to Aero-Med, a division of Cardinal Health.

The companies have signed a distribution agreement, according to which Aero-Med will market the device in the six New England states initially through direct sales and later through an e-commerce platform. Aero-Med is targeting large specific markets such as anti-aging, functional and integrative health and wellness treatment practitioners in the US.

"Earlens intends to complete the financing in Q3 this year by raising an additional $14m, which will be utilised to launch its Light Driven Hearing Aid."

Molecular diagnostics company Transplant Genomics (TGI) has announced collaboration with Mayo Clinic Center for Individualized Medicine to develop, validate and market diagnostic tests for organ transplant recipients.

The multi-year agreement includes assessment of TGI’s TruGraf test for renal transplant monitoring, and co-development of new tests for exploratory studies in heart and liver transplantation.

Guardant Health, a cancer-related diagnostic technologies developer, and Teva Pharmaceutical subsidiary Oncotest-Teva have signed an exclusive distribution and marketing agreement for commercialising the former’s ground-breaking liquid biopsy test, Guardant360.

Pursuant to the agreement, Oncotest-Teva will market Guardant360, a non-invasive genomic sequencing test for patients with advanced cancer, in Israel, while Guardant Health will perform all testing at its facilities in Redwood City, California, US.

Image: Akers Biosciences’ OxiChek is the first disposable breath test. Photo: courtesy of Akers Biosciences.